Polygenic Risk Prediction using Gradient Boosted Trees Captures Non-Linear Genetic Effects and Allele Interactions in Complex Phenotypes

Competing Interest Statement

B Psaty serves on the Steering Committee of the Yale Open Data Access Project funded by Johnson & Johnson. All other co-authors declare no conflict of interest.

Clinical Trial

This is not a clinical trial.

Funding Statement

Molecular data for the Trans-Omics in Precision Medicine (TOPMed) program was supported by the National Heart, Lung and Blood Institute (NHLBI). Genome sequencing for "NHLBI TOPMed: Whole Genome Sequencing and Related Phenotypes in the Framingham Heart Study" (phs000974.v4.p3) was performed at the Broad Institute Genomics Platform (3R01HL092577-06S1, 3U54HG003067-12S2). Genome sequencing for "NHLBI TOPMed: The Jackson Heart Study" (phs000964.v1.p1) was performed at the Northwest Genomics Center (HHSN268201100037C). Genome sequencing for the "NHLBI TOPMed: The Atherosclerosis Risk in Communities Study" (phs001211.v3.p2) was performed at the Broad Institute Genomics Platform (3R01HL092577-06S1) and the Baylor College of Medicine Human Genome Sequencing Center (HHSN268201500015C, 3U54HG003273-12S2). Genome sequencing for "NHLBI TOPMed: Coronary Artery Risk Development in Young Adults Study" (phs001612.v1.p1) was performed at the Baylor College of Medicine Human Genome Sequencing Center (HHSN268201600033I). Genome sequencing for "NHLBI TOPMed:Cleveland Family Study" (phs000954.v3.p2) was performed at the Northwest Genomics Center (3R01HL098433-05S1, HHSN268201600032I). Genomics sequencing for "NHLBI TOPMed: Cardiovascular Health Study" (phs001368.v2.p1) was performed at the Baylor College of Medicine Human Genome Sequencing Center (3U54HG003273-12S2, HHSN268201500015C, HHSN268201600033I). Genome sequencing for "NHLBI TOPMed: Hispanic Community Health Study/Study of Latinos" (phs001395.v1.p1) was performed at the Baylor College of Medicine Human Genome Sequencing Center (HHSN268201600033I). Genome sequencing for "NHLBI TOPMed: Multi-Ethnic Study of Atherosclerosis" (phs001416.v2.p1) was performed at Broad Institute Genomics Platform (HHSN268201500014C, 3U54HG003067-13S1). Core support including centralized genomic read mapping and genotype calling, along with variant quality metrics and filtering were provided by the TOPMed Informatics Research Center (3R01HL-117626-02S1; contract HHSN268201800002I). Core support including phenotype harmonization, data management, sample-identity QC, and general program coordination were provided by the TOPMed Data Coordinating Center (R01HL-120393; U01HL-120393; contract HHSN268201800001I). We gratefully acknowledge the studies and participants who provided biological samples and data for TOPMed. The Genome Sequencing Program (GSP) was funded by the National Human Genome Research Institute (NHGRI), the National Heart, Lung, and Blood Institute (NHLBI), and the National Eye Institute (NEI). The GSP Coordinating Center (U24 HG008956) contributed to cross-program scientific initiatives and provided logistical and general study coordination. The Centers for Common Disease Genomics (CCDG) program was supported by NHGRI and NHLBI, and whole genome sequencing was performed at the Baylor College of Medicine Human Genome Sequencing Center (UM1 HG008898 and R01HL059367). ME, TS, and SR are supported by NHLBI grants R35HL135818 to SR. GMP is supported by R01HL142711 from the NHLBI. The project described was supported by the National Center for Advancing Translational Sciences, National Institutes of Health, through grant KL2TR002490 to LMR. PdV was supported by American Heart Association grant number 18CDA34110116 and NHLBI grant number R01HL146860. The views expressed in this manuscript are those of the authors and do not necessarily represent the views of the National Heart, Lung, and Blood Institute; the National Institutes of Health; or the U.S. Department of Health and Human Services.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study was approved by the Mass General Brigham IRB.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes